Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factorrelated apoptosis-inducing ligand (Apo2 ligand) in vivo

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 863-869

  Weber, Christian ^a,h   Weber, Tobias ^a   Gellert, Nina ^a   Schröder, Andreas ^a   Erl, Wolfgang ^a   Neuzil, Jiri ^a,b   Terman, Alexei ^b   Brunk, Ulf T ^b   Lu, Min ^c   Coffey, Robert J ^c   Andera, Ladislav ^d   Korinek, Vladimir ^d   Lahm, Harald ^a   Fariss, Marc W ^e   Sattler, Wolfgang ^f   Ucker, David S ^g  

^a UNIVERSITY OF MUNICH   (Germany)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c VANDERBILT UNIVERSITY   (United States)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^e WASHINGTON STATE UNIVERSITY   (United States)

^f UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF ILLINOIS   (United States)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; DOXORUBICIN; FLUOROURACIL; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ALPHA-TOCOPHEROL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG SYNERGISM; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NEOPLASM INVASIVENESS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; VITAMIN E; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036301439     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Apoptosis in human disease: A new skin for the old ceremony?
2. Apoptosis signalling
3. New insights into p53 regulation and gene therapy for cancer
4. Apoptosis and cell division
5. p53 family genes: Structural comparison, expression, and mutation
6. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
7. wafl/Cip1 via C/EBPβ
8. Transcription abnormalities potentiate apoptosis of normal human fibroblasts
9. Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: Increased binding of cyclin A negatively regulates E2F transactivation activity
10. The selective antiproliferative effects of α-tocopheryl hemisuccinate and cholesteryl hemisucinate on murine leukemia cells result from the action of the intact compounds
11. α-tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation
12. Induction of cancer cell apoptosis by α-tocopheryl succinate: Molecular pathways and structural requirements
13. c-Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells
14. Growth inhibition of MCF-7 and MCF-10A human breast cells by α-tocopheryl hemisuccinate, cholesteryl hemisuccinate and their ether analogs
15. Selective cancer cell killing by α-tocopheryl succinate
16. Protection against carbon tetrachloride-induced hepatotoxicity by pretreating rats with the hemisuccinate esters of tocopherol and cholesterol
17. Caspase-dependent Cdk activity is a requisite effector of apoptotic death events
18. Effect of different oxygen pressures and N, N'-diphenyl-p-phenylenediamine on Adriamycin toxicity to cultured neonatal rat heart myocytes
19. Establishment of human colonic epithelial cells in long-term culture
20. Nuclear factor-KB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells
21. α-tocopheryl succinate protects hepatocytes from chemical-induced toxicity under physiological calcium conditions
22. Lipoprotein-associated α-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells
23. Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells
24. m loss, caspase-9 activity, and apoptosis in Jurkat cells
25. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
26. Viral caspase inhibitors CrmA and p35
27. Membrane-targeted green fluorescent protein reliably and uniquely marks cells through apoptotic death
28. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4
29. Stocker non-antioxidant roles
30. Administration of the Tris salt of α-tocopheryl hemisuccinate inactivates CYP2E1, enhances microsomal α-tocopherol levels, and protects against carbon tetrachloride-induced hepatotoxicity
31. Protection of zidovudine-induced toxicity against murine erythroid progenitor cells by vitamin E
32. Vitamin E succinate promotes breast cancer tumor dormancy
33. Choosing anticancer drug targets in the postgenomic era
34. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
35. r 43,000 Fas in VES-triggered apoptosis
36. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis
37. Tumoricidal activity of tumor necrosis factor-related apoptosis inducing ligand in vivo
38. Safety and antitumor activity of recombinant soluble Apo2 ligand
39. Molecular determinants of response to TRAIL in killing of normal and cancer cells
40. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
41. Combination of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cells
42. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
43. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer
44. L-overexpressing chemotherapy resistant tumor cells
45. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
46. Coenzyme Q blocks chemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection
47. L, and Apafform a ternary complex
48. α-tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-κB mobilization
49. Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage
50. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
51. NF-κB inducers up-regulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling
52. The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells
53. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells
54. Inhibition of NF-κB activity enhances TRAIL mediated apoptosis in breast cancer cell lines
55. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
56. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
57. Effects of supplemental α-tocopherol and β-carotene on colorectal cancer: Results from a controlled trial